Source comparison
PT-141 & Melanotan-2: Central vs Peripheral Effects
A 2019 Phase 3 trial published in JAMA Internal Medicine found that bremelanotide (PT-141) produced statistically significant improvements in desire and arousal in premenopausal women with hypoactive sexual desire disorder. But the mechanism had nothing to do
This comparison does not assign a generated winner or score.
- A 2019 Phase 3 trial published in JAMA Internal Medicine found that bremelanotide (PT-141) produced statistically significant improvements in desire and arousal in premenopausal women with hypoactive sexual desire disorder. But the mechanism had nothing to do with hormone replacement or vascular dilation. PT-141 works centrally, binding melanocortin receptors in the hypothalamus to modulate dopamine and norepinephrine signaling pathways that drive sexual arousal independently of blood flow or genital response. Melanotan-2, structurally similar but receptor-nonselective, produces pigmentation, metabolic shifts, and central effects simultaneously. Making it a fundamentally different tool despite sharing the same peptide backbone.
- Our team has worked with research-grade melanocortin peptides for years. The confusion between PT-141 and Melanotan-2 is persistent because both are cyclic heptapeptides derived from alpha-MSH (melanocyte-stimulating hormone), and both can influence arousal pathways. The difference is receptor selectivity. And that selectivity determines everything from side effect profiles to research applications.
- What is the difference between PT-141 and Melanotan-2 in terms of central versus peripheral effects?
- PT-141 (bremelanotide) acts primarily on central melanocortin receptors MC4R and MC3R in the hypothalamus, driving dopamine-mediated arousal signaling without peripheral pigmentation. Melanotan-2 is a nonselective agonist that binds MC1R in melanocytes (producing tanning), MC4R centrally (affecting appetite and arousal), and MC3R (modulating energy homeostasis). The result: PT-141 produces arousal effects with minimal pigmentation, while Melanotan-2 affects skin tone, metabolic rate, appetite suppression, and central arousal pathways simultaneously. Each peptide's receptor profile defines its primary research utility. PT-141 for isolated central signaling studies, Melanotan-2 for multi-system melanocortin research.
- Yes, both peptides can influence arousal. But they arrive at that outcome through different receptor mechanisms, with different collateral effects, at different doses. PT-141 was developed specifically to separate the central arousal effect from the peripheral pigmentation and metabolic effects that made Melanotan-2 unsuitable for clinical sexual dysfunction treatment. Melanotan-2 binds all five melanocortin receptor subtypes (MC1R through MC5R) with varying affinity, while PT-141 was structurally modified to increase selectivity for MC4R and reduce MC1R binding. This article covers the receptor pharmacology that produces these divergent effects, the side effect profiles that result from receptor selectivity, and the research applications where each peptide's mechanism matters.